Instructions on how long it takes to safely stop taking Selinesol (Silvio) tablets

Selinexor (Selinexor) is a selective nuclear export inhibitor (SINE), mainly used to treat patients with relapsed or refractory multiple myeloma and certain lymphomas. It inhibits the XPO1 protein and blocks the export of tumor suppressor proteins in the nucleus of cancer cells, thereby inducing cancer cell apoptosis. As a targeted anti-tumor drug, selinesol is often used in combination with low-dose dexamethasone or other chemotherapy drugs to improve efficacy.

The timing of discontinuation of selinesol needs to be based on the patient's efficacy, tolerability and adverse reactions. Common adverse reactions include thrombocytopenia, anemia, nausea, fatigue and decreased appetite. During treatment, if serious or intolerable adverse reactions occur, the doctor may recommend temporary discontinuation of the drug or adjustment of the dose rather than complete and continuous discontinuation of the drug. Safe discontinuation of medication needs to be done under the guidance of a professional doctor to avoid rapid progression or recurrence of the disease.

For most patients, short-term drug withdrawal is usually used to alleviate adverse reactions. The efficacy may be temporarily weakened during drug withdrawal, but short-term drug withdrawal generally does not lead to significant worsening of the condition. In clinical practice, doctors often recommend observing the patient's blood picture, liver and kidney function, and symptom improvement before deciding whether to resume medication or adjust the dose. The specific duration of discontinuation varies with individual patient differences and treatment response and requires individualized assessment.

While taking selinesol, patients should strictly follow the doctor's instructions and conduct regular monitoring of hematological and biochemical indicators. If the medication needs to be discontinued, you should communicate with the attending doctor in time and follow the gradual discontinuation or suspension of dose adjustment plan to ensure safety. After stopping the drug, the condition should be closely followed up and tumor markers and clinical symptoms should be observed so that subsequent treatment plans can be adjusted in a timely manner to ensure both efficacy and safety.

Reference link:https://www.drugs.com